Core Viewpoint - The company has submitted an application for a Phase III clinical trial of IMM2510 for the treatment of immune therapy-resistant non-small cell lung cancer (NSCLC) to the National Medical Products Administration of China [1] Group 1: Clinical Trial Developments - The company has recently submitted two Phase III registration clinical trials for different types of lung cancer [1] - The I phase study data presented at the 2025 World Lung Cancer Conference showed an objective response rate (ORR) of 35.3% and a disease control rate (DCR) of 76.5% among 17 evaluable patients with advanced squamous NSCLC who had previously received immune therapy [1] - The median duration of response (DoR) was reported as 7.59 months, and the median progression-free survival (PFS) was 9.4 months [1] Group 2: Future Plans - Based on the promising results from the I phase study, the company plans to further validate the efficacy and safety of IMM2510 through the Phase III clinical trials [1] - The aim is to provide more effective treatment options for lung cancer patients [1]
宜明昂科-B(01541)：提交IMM2510的III期临床试验申请